A novel technique of serial biopsy in mouse brain tumour models

Sasha Rogers, Hilary Hii, Joel Huang, Mathew Ancliffe, Nick G. Gottardo, Peter Dallas, Sharon Lee, Raelene Endersby

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Biopsy is often used to investigate brain tumour-specific abnormalities so that treatments can be appropriately tailored. Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model. In order to determine the feasibility of conducting serial brain biopsies in mouse models with minimal morbidity, and if successful, investigate whether this can facilitate evaluation of chemotherapeutic response, an orthotopic model of glioblastoma was used. Immunodeficient mice received cortical implants of the human glioblastoma cell line, U87MG, modified to express the constitutively-active EGFR mutant, EGFRvIII, GFP and luciferase. Tumour growth was monitored using bioluminescence imaging. Upon attainment of a moderate tumour size, free-hand biopsy was performed on a subgroup of animals. Animal monitoring using a neurological severity score (NSS) showed that all mice survived the procedure with minimal perioperative morbidity and recovered to similar levels as controls over a period of five days. The technique was used to evaluate dacomitinib-mediated inhibition of EGFRvIII two hours after drug administration. We show that serial tissue samples can be obtained, that the samples retain histological features of the tumour, and are of sufficient quality to determine response to treatment. This approach represents a significant advance in murine brain surgery that may be applicable to other brain tumour models. Importantly, the methodology has the potential to accelerate the preclinical in vivo drug screening process. 

Original languageEnglish
Article numbere0175169
Number of pages13
JournalPLoS One
Volume12
Issue number4
DOIs
Publication statusPublished - 10 Apr 2017

Fingerprint

Biopsy
Brain Neoplasms
Tumors
biopsy
Brain
Glioblastoma
brain
neoplasms
mice
Neoplasms
Morbidity
Animals
drugs
Preclinical Drug Evaluations
morbidity
Pharmaceutical Preparations
Bioluminescence
animal models
Luciferases
methodology

Cite this

Rogers, S., Hii, H., Huang, J., Ancliffe, M., Gottardo, N. G., Dallas, P., ... Endersby, R. (2017). A novel technique of serial biopsy in mouse brain tumour models. PLoS One, 12(4), [e0175169]. https://doi.org/10.1371/journal.pone.0175169
Rogers, Sasha ; Hii, Hilary ; Huang, Joel ; Ancliffe, Mathew ; Gottardo, Nick G. ; Dallas, Peter ; Lee, Sharon ; Endersby, Raelene. / A novel technique of serial biopsy in mouse brain tumour models. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{cc9d28ffc0f34d86930c648bdd1906ab,
title = "A novel technique of serial biopsy in mouse brain tumour models",
abstract = "Biopsy is often used to investigate brain tumour-specific abnormalities so that treatments can be appropriately tailored. Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model. In order to determine the feasibility of conducting serial brain biopsies in mouse models with minimal morbidity, and if successful, investigate whether this can facilitate evaluation of chemotherapeutic response, an orthotopic model of glioblastoma was used. Immunodeficient mice received cortical implants of the human glioblastoma cell line, U87MG, modified to express the constitutively-active EGFR mutant, EGFRvIII, GFP and luciferase. Tumour growth was monitored using bioluminescence imaging. Upon attainment of a moderate tumour size, free-hand biopsy was performed on a subgroup of animals. Animal monitoring using a neurological severity score (NSS) showed that all mice survived the procedure with minimal perioperative morbidity and recovered to similar levels as controls over a period of five days. The technique was used to evaluate dacomitinib-mediated inhibition of EGFRvIII two hours after drug administration. We show that serial tissue samples can be obtained, that the samples retain histological features of the tumour, and are of sufficient quality to determine response to treatment. This approach represents a significant advance in murine brain surgery that may be applicable to other brain tumour models. Importantly, the methodology has the potential to accelerate the preclinical in vivo drug screening process. ",
author = "Sasha Rogers and Hilary Hii and Joel Huang and Mathew Ancliffe and Gottardo, {Nick G.} and Peter Dallas and Sharon Lee and Raelene Endersby",
year = "2017",
month = "4",
day = "10",
doi = "10.1371/journal.pone.0175169",
language = "English",
volume = "12",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science (PLoS)",
number = "4",

}

Rogers, S, Hii, H, Huang, J, Ancliffe, M, Gottardo, NG, Dallas, P, Lee, S & Endersby, R 2017, 'A novel technique of serial biopsy in mouse brain tumour models' PLoS One, vol. 12, no. 4, e0175169. https://doi.org/10.1371/journal.pone.0175169

A novel technique of serial biopsy in mouse brain tumour models. / Rogers, Sasha; Hii, Hilary; Huang, Joel; Ancliffe, Mathew; Gottardo, Nick G.; Dallas, Peter; Lee, Sharon; Endersby, Raelene.

In: PLoS One, Vol. 12, No. 4, e0175169, 10.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel technique of serial biopsy in mouse brain tumour models

AU - Rogers, Sasha

AU - Hii, Hilary

AU - Huang, Joel

AU - Ancliffe, Mathew

AU - Gottardo, Nick G.

AU - Dallas, Peter

AU - Lee, Sharon

AU - Endersby, Raelene

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Biopsy is often used to investigate brain tumour-specific abnormalities so that treatments can be appropriately tailored. Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model. In order to determine the feasibility of conducting serial brain biopsies in mouse models with minimal morbidity, and if successful, investigate whether this can facilitate evaluation of chemotherapeutic response, an orthotopic model of glioblastoma was used. Immunodeficient mice received cortical implants of the human glioblastoma cell line, U87MG, modified to express the constitutively-active EGFR mutant, EGFRvIII, GFP and luciferase. Tumour growth was monitored using bioluminescence imaging. Upon attainment of a moderate tumour size, free-hand biopsy was performed on a subgroup of animals. Animal monitoring using a neurological severity score (NSS) showed that all mice survived the procedure with minimal perioperative morbidity and recovered to similar levels as controls over a period of five days. The technique was used to evaluate dacomitinib-mediated inhibition of EGFRvIII two hours after drug administration. We show that serial tissue samples can be obtained, that the samples retain histological features of the tumour, and are of sufficient quality to determine response to treatment. This approach represents a significant advance in murine brain surgery that may be applicable to other brain tumour models. Importantly, the methodology has the potential to accelerate the preclinical in vivo drug screening process. 

AB - Biopsy is often used to investigate brain tumour-specific abnormalities so that treatments can be appropriately tailored. Dacomitinib (PF-00299804) is a tyrosine kinase inhibitor (TKI), which is predicted to only be effective in cancers where the targets of this drug (EGFR, ERBB2, ERBB4) are abnormally active. Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model. In order to determine the feasibility of conducting serial brain biopsies in mouse models with minimal morbidity, and if successful, investigate whether this can facilitate evaluation of chemotherapeutic response, an orthotopic model of glioblastoma was used. Immunodeficient mice received cortical implants of the human glioblastoma cell line, U87MG, modified to express the constitutively-active EGFR mutant, EGFRvIII, GFP and luciferase. Tumour growth was monitored using bioluminescence imaging. Upon attainment of a moderate tumour size, free-hand biopsy was performed on a subgroup of animals. Animal monitoring using a neurological severity score (NSS) showed that all mice survived the procedure with minimal perioperative morbidity and recovered to similar levels as controls over a period of five days. The technique was used to evaluate dacomitinib-mediated inhibition of EGFRvIII two hours after drug administration. We show that serial tissue samples can be obtained, that the samples retain histological features of the tumour, and are of sufficient quality to determine response to treatment. This approach represents a significant advance in murine brain surgery that may be applicable to other brain tumour models. Importantly, the methodology has the potential to accelerate the preclinical in vivo drug screening process. 

UR - http://www.scopus.com/inward/record.url?scp=85017269352&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0175169

DO - 10.1371/journal.pone.0175169

M3 - Article

VL - 12

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 4

M1 - e0175169

ER -

Rogers S, Hii H, Huang J, Ancliffe M, Gottardo NG, Dallas P et al. A novel technique of serial biopsy in mouse brain tumour models. PLoS One. 2017 Apr 10;12(4). e0175169. https://doi.org/10.1371/journal.pone.0175169